Armata Pharmaceuticals Inc
-0.0525 (-1.84%)
Upgrade to Real-Time
Regular Market
Volume 1,028
Bid Price
Ask Price
News -
Day High 2.94


52 Week Range


Day Low 2.8075
Company Name Stock Ticker Symbol Market Type
Armata Pharmaceuticals Inc ARMP AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0525 -1.84% 2.8075 10:54:41
Open Price Low Price High Price Close Price Prev Close
2.94 2.8075 2.94 2.86
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
20 1,028 $ 2.87 $ 2,953 - 0.8311 - 5.79
Last Trade Time Type Quantity Stock Price Currency
11:02:31 1 $ 2.8051 USD


Draw Mode:

Armata Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 101.48M 36.14M 10.74M $ 1.17M $ - -0.97 -2.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 1.70%

more financials information »

Armata Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARMP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.453.452.72243.018,887-0.6425-18.62%
1 Month1.363.761.362.7720,9191.45106.43%
3 Months3.293.760.83112.0123,038-0.4825-14.67%
6 Months4.205.000.83112.3713,303-1.39-33.15%
1 Year5.125.790.83113.2410,799-2.31-45.17%
3 Years3.8410.480.83114.0620,329-1.03-26.89%
5 Years4.9010.480.83114.1835,122-2.09-42.7%

Armata Pharmaceuticals Description

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.